Dear readers,
The significant technological improvements achieved in the recent years have increased the diagnostic accuracy of CT imaging in the context of prostate cancer. The valuable role of CT, also performed in conjunction with positron emission tomography (PET), has been widely demonstrated in clinical studies, particularly for initial staging and restaging after biochemical failure, for the identification of the site of disease and localisation of recurrences and metastases.
This topic is discussed in detail by Prof. Torregrosa, from Valencia (Spain), in a new videographics presented in this Newsletter, where the main messages of her talk are accompanied and reinforced by very suggestive infographics.
The two scientific papers included in the “Selected literature” section provide evidence for the adoption of CT and PET/CT in risk stratification and prediction of treatment outcome, and in restaging and evaluating therapy response in prostate cancer, respectively.
Finally, a clinical case from the MDCT.net archive illustrates the usefulness of contrast-enhanced CT in detecting possible metastases in a patient with prostate cancer.
As usual, suggestions for topics to be covered in future issues of this newsletter are welcome:
please send your proposals to us at editorial@mdct.net.
From the MDCT.net team
